Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ONO-4578 alone and with nivolumab in advanced solid tumors
jRCT2080223441Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 and nivolumab in Nonhematologic neoplasms, gastric cancer (GC) and colorectal cancer (CRC) (4 arms), sponsored by Ono Pharmaceutical. Started Jan 2017; status: completed.
02
Drugs
ONO-4578nivolumab
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080223441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223441.